CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$14.10-5.37%
Price as of Jul 20, 2026
CRVS financials
Corvus Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $105.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | -$105.0K | $0.00 | $0.00 | $0.00 |
| Operating expenses | $42.9M | $27.5M | $23.4M | $32.6M |
| Operating income | -$43.0M | -$27.5M | -$23.4M | -$32.6M |
| Net income | -$15.3M | -$62.3M | -$27.0M | -$41.3M |
| EBITDA | -$15.2M | -$62.2M | -$26.9M | -$40.9M |
| Basic EPS | $-0.19 | $-1.02 | $-0.56 | $-0.89 |
| Diluted EPS | $-0.53 | $-1.02 | $-0.56 | $-0.89 |
| Balance sheet | ||||
| Cash & equivalents | $4.6M | $8.7M | $12.6M | $13.2M |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M |
| Total liabilities | $9.9M | $36.3M | $6.9M | $12.1M |
| Stockholders’ equity | $61.2M | $32.6M | $38.7M | $56.1M |
| Total debt | $937.0K | $1.1M | $1.4M | $2.6M |
| Net debt | -$3.6M | -$7.6M | -$11.2M | -$10.6M |
| Cash flow | ||||
| Operating cash flow | -$32.8M | -$25.4M | -$23.9M | -$27.0M |
| Capital expenditure | -$174.0K | $0.00 | -$34.0K | -$269.0K |
| Free cash flow | -$33.0M | -$25.4M | -$24.0M | -$27.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |